Beta Drugs Financial Statements
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | - | - | - | - |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | -- | -- | -- | -- |
| Op profit growth | -- | -- | -- | -- |
| EBIT growth | -- | -- | -- | -- |
| Net profit growth | -- | -- | -- | -- |
| Profitability ratios (%) | ||||
| OPM | -- | -- | -- | -- |
| EBIT margin | -- | -- | -- | -- |
| Net profit margin | -- | -- | -- | -- |
| RoCE | -- | -- | -- | -- |
| RoNW | -- | -- | -- | -- |
| RoA | -- | -- | -- | -- |
| Per share ratios () | ||||
| EPS | -- | -- | -- | -- |
| Dividend per share | -- | -- | -- | -- |
| Cash EPS | -- | -- | -- | -- |
| Book value per share | -- | -- | -- | -- |
| Valuation ratios | ||||
| P/E | -- | -- | -- | -- |
| P/CEPS | -- | -- | -- | -- |
| P/B | -- | -- | -- | -- |
| EV/EBIDTA | -- | -- | -- | -- |
| Payout (%) | ||||
| Dividend payout | -- | -- | -- | -- |
| Tax payout | -- | -- | -- | -- |
| Liquidity ratios | ||||
| Debtor days | -- | -- | -- | -- |
| Inventory days | -- | -- | -- | -- |
| Creditor days | -- | -- | -- | -- |
| Leverage ratios | ||||
| Interest coverage | -- | -- | -- | -- |
| Net debt / equity | -- | -- | -- | -- |
| Net debt / op. profit | -- | -- | -- | -- |
| Cost breakup () | ||||
| Material costs | -- | -- | -- | -- |
| Employee costs | -- | -- | -- | -- |
| Other costs | -- | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | - | - | - | - |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| yoy growth (%) | -- | -- | -- | -- |
| Raw materials | -- | -- | -- | -- |
| As % of sales | -- | -- | -- | -- |
| Employee costs | -- | -- | -- | -- |
| As % of sales | -- | -- | -- | -- |
| Other costs | -- | -- | -- | -- |
| As % of sales | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- |
| OPM | -- | -- | -- | -- |
| Depreciation | -- | -- | -- | -- |
| Interest expense | -- | -- | -- | -- |
| Other income | -- | -- | -- | -- |
| Profit before tax | -- | -- | -- | -- |
| Taxes | -- | -- | -- | -- |
| Tax rate | -- | -- | -- | -- |
| Minorities and other | -- | -- | -- | -- |
| Adj. profit | -- | -- | -- | -- |
| Exceptional items | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- |
| yoy growth (%) | -- | -- | -- | -- |
| NPM | -- | -- | -- | -- |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | - | - | - | - |
|---|---|---|---|---|
| Profit before tax | -- | -- | -- | -- |
| Depreciation | -- | -- | -- | -- |
| Tax paid | -- | -- | -- | -- |
| Working capital | -- | -- | -- | -- |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | -- | -- | -- | -- |
| Capital expenditure | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- |
| Equity raised | -- | -- | -- | -- |
| Investments | -- | -- | -- | -- |
| Debt financing/disposal | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- |
| Other items | -- | -- | -- | -- |
| Net in cash | -- | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2019 | Mar-2018 | - | - |
|---|---|---|---|---|
| Equity capital | 8.65 | 8.65 | -- | -- |
| Preference capital | -- | -- | -- | -- |
| Reserves | 32.30 | 24.20 | -- | -- |
| Net worth | 40.90 | 32.90 | -- | -- |
| Minority interest | ||||
| Debt | 20 | 7.50 | -- | -- |
| Deferred tax liabilities (net) | 0.15 | 0.15 | -- | -- |
| Total liabilities | 61 | 40.50 | -- | -- |
| Fixed assets | 32.40 | 14.50 | -- | -- |
| Intangible assets | ||||
| Investments | 0.35 | -- | -- | -- |
| Deferred tax asset (net) | 0.29 | -- | -- | -- |
| Net working capital | 24.70 | 14.10 | -- | -- |
| Inventories | 9.53 | 2.80 | -- | -- |
| Inventory Days | -- | -- | -- | -- |
| Sundry debtors | 25 | 14.40 | -- | -- |
| Debtor days | -- | -- | -- | -- |
| Other current assets | 11.80 | 5.89 | -- | -- |
| Sundry creditors | (16) | (6.10) | -- | -- |
| Creditor days | -- | -- | -- | -- |
| Other current liabilities | (6.10) | (3) | -- | -- |
| Cash | 3.30 | 11.90 | -- | -- |
| Total assets | 61 | 40.50 | -- | -- |
- Switch to
-
ConsolidatedStandalone
| Beta Drugs Ltd Report not showing data |
|---|
